Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00279214 · ClinicalTrials.gov registry record · Phase 4
Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients With Septic Shock
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 43
- Enrollment target
NCT00279214 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 43 participants.
The verdict
NCT00279214, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 43 participants
- Enrollment target
Study Summary
The study will evaluate the vasopressor requirement, hemodynamic response and measures of tissue perfusion in patients with septic shock receiving an infusion of drotrecogin alfa (activated) compared to patients not receiving drotrecogin alfa (activated).
Interventions
- DRUG drotrecogin alfa (activated)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2005-11 |
| Est. Completion | 2007-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00279214
The ClinicalTrials.gov registry entry for NCT00279214 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which drotrecogin alfa (activated) is the first listed.
NCT00279214 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00279214 about?
NCT00279214 is a clinical study titled "Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients With Septic Shock". The study will evaluate the vasopressor requirement, hemodynamic response and measures of tissue perfusion in patients with septic shock receiving an infusion of drotrecogin alfa (activated) compared to patients not receiving drotrecogin alfa (activated).
What is the current status of trial NCT00279214?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 43 participants. The study started on 2005-11. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00279214?
The interventions under investigation include: drotrecogin alfa (activated) (DRUG).
Who is sponsoring clinical trial NCT00279214?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.